AB “Ignitis grupė“ (hereinafter – the Group) informs that on 24 February 2026, as part of its asset rotation program and in order to ensure proper implementation of the decision of the European Commission (hereinafter – the EC), it has agreed with Quaero European Infrastructure Fund III, a fund managed by Quaero Capital SA (hereinafter – Quaero Capital), on the sale of a 49% stake in UAB Vilniaus kogeneracinė jėgainė (hereinafter – Vilnius CHP) managed by the Group. This is one of the largest foreign direct ...

Nanterre, 25 February 2026 VINCI launches an issue of bonds exchangeable for existing ordinary shares of Groupe ADP due 2031 for a nominal amount of €500m VINCI (the “Issuer”), owning 8.0% of Groupe ADP’s share capital, announces its intention to issue a bond exchangeable for Groupe ADP shares (the “Shares”). VINCI has decided to issue a €500 million bond exchangeable into Shares (the “Bonds” and together with the Shares, the “Securities”) as a competitive funding source, allowing to potentially monetize a ...

Core Insights - Novonesis achieved strong organic sales growth of 7% in 2025, with an adjusted EBITDA margin of 37.1% and robust cash flow despite currency challenges [1][4] - The company anticipates a positive start to 2026, projecting continued growth across all sales areas and margin expansion [1][4] Financial Performance - Organic sales growth was broad-based, with Food & Health segment growing at 8% and Planetary Health at 6% [4] - Emerging Markets saw a 9% organic growth, while Developed Markets grew by 6% [4] - Adjusted net profit increased by 17%, and free cash flow before acquisitions was EUR 770.4 million, representing 19% of sales [4] - Proposed dividend of DKK 4.25 per share, with a payout ratio of 58.4% of adjusted net profit for 2025 [4] Strategic Developments - The company launched 33 new products in 2025, with innovations from the last five years accounting for 25% of sales [4] - Novonesis achieved all six environmental and social targets for 2025 and is on track for future commitments [4] 2026 Outlook - The company expects organic sales growth between 5-7% for 2026, with some uncertainty regarding consumer sentiment [4] - The outlook includes approximately 1%-point contribution from positive pricing and sales synergies, alongside a near 1%-point negative impact from exiting certain countries [4] - Adjusted EBITDA margin is projected to be between 37-38%, with expected margin expansion despite currency headwinds [4]

Group 1: Outlook for 2026 - AL Sydbank projects moderate growth in the Danish economy for 2026, with profit after tax expected to be in the range of DKK 3,500-4,000 million, assuming the Danish central bank maintains the certificate of deposit rate [1] Group 2: Share Buyback Program - The Board of Directors has approved a share buyback program amounting to DKK 1,100 million, aimed at reducing the Bank's share capital [2] - The share buyback program will commence on March 2, 2026, and is scheduled to be completed by January 31, 2027 [3] - Danske Bank A/S has been selected to manage the share buyback program, which will adhere to the Safe Harbour rules as per EU regulations [4] Group 3: Purchase Guidelines - Shares will not be purchased at a price exceeding the higher of the last independent trade price or the highest current independent purchase bid on the trading venue [5] - Daily purchases will be limited to 25% of the average daily volume of shares traded in the preceding 20 trading days [5] - AL Sydbank will disclose the number and value of repurchased shares every week on the first banking day [5] Group 4: Program Flexibility - AL Sydbank reserves the right to suspend or terminate the share buyback program at any time, with such decisions to be announced publicly [6]

Group 1 - The Annual General Meeting of AL Sydbank A/S is scheduled for Thursday, March 19, 2026, at 3:00 PM [1] - The notice and agenda for the general meeting have been attached to the announcement [1]

Core Viewpoint - Worldline is selling its Indian payment activities to BillDesk for an estimated equity value of approximately €60 million, while entering a long-term technology partnership to ensure operational continuity and leverage Worldline's advanced payment software [2][3]. Group 1: Transaction Details - The enterprise value of the transaction is approximately €37 million, with an estimated equity value at closing of around €60 million [5]. - The revenue, Adjusted EBITDA, and free cash flow deconsolidation impact from this transaction are estimated at approximately €90 million, €8 million, and free cash flow neutral on a full-year basis, respectively [5]. - The transaction is expected to close in the second half of 2026, subject to customary processes and applicable laws [7]. Group 2: Strategic Implications - This sale is a significant step in Worldline's strategy to focus on core payment activities in Europe, streamline operations, and optimize resource allocation [6]. - The estimated cash proceeds from this transaction will enhance Worldline's financial profile and strategic flexibility, allowing for capital redeployment towards core activities [6]. Group 3: Commitment to India - Worldline remains committed to India as a strategic hub for talent and innovation, planning to evolve its Global Competence Centres into innovation hubs to build critical payment talent pools and drive automation and AI at scale [4].

Core Insights - Ageas reported strong financial results for the full year 2025, highlighting a transformational year for the company [1][2] - The company achieved a 9% increase in inflows, with a notable 33% rise in net operating results, reaching EUR 1.65 billion [1][2] - Ageas proposed a gross cash dividend of EUR 3.75, reflecting its commitment to shareholders [1][2] Financial Performance - Total inflows reached EUR 19.6 billion, marking a 9% increase compared to 2024 [1] - The net operating result was EUR 1.65 billion, up 33% from the previous year [1] - Free cash flow amounted to EUR 774 million, representing a 19% increase year-over-year [1] - The proposed gross cash dividend for 2025 is EUR 3.75, a 7% increase from 2024 [1] Strategic Developments - The acquisition of esure positioned Ageas as the 3rd largest personal lines insurer in the UK, while full ownership of Belgium's leading insurer AG was secured [2] - The Elevate27 strategy gained momentum, allowing the company to raise financial targets twice during the year [2] - Key strategic initiatives included a focus on ageing, SMEs, and enhanced use of Data & AI [2] Sustainability and ESG Performance - Ageas made significant progress in sustainability, earning positive recognition from employees and customers [2] - The company ranks in the top quartile with three of the five ESG rating agencies it engages with [2] - The portfolio of sustainable products continued to grow, reflecting the trust of customers and employees [2]

Core Insights - Bureau Veritas achieved sector-leading organic revenue growth of 6.5% in FY 2025, with a strong margin improvement to 16.3% [1][4][10] - The company has a positive growth outlook for 2026, expecting continued margin expansion and a new EUR 200 million share buyback program [1][4][8] Financial Performance - Full-year revenue reached EUR 6,466.4 million, up 6.5% organically, with Q4 organic growth at 6.3% [4][9][40] - Adjusted operating profit increased to EUR 1,052.9 million, a 5.7% rise from EUR 996.2 million in FY 2024, with an adjusted operating margin of 16.3% [4][9][37] - Adjusted net profit was EUR 631.4 million, up 1.7% from EUR 620.7 million in FY 2024, with adjusted EPS at EUR 1.42, reflecting a 2.8% increase [4][9][47] - Free cash flow totaled EUR 824.2 million, a 3.9% organic increase, with cash conversion at 107% [4][9][50] Strategic Developments - The company executed nine bolt-on acquisitions in 2025, contributing EUR 96 million in annualized revenue, while also divesting two non-core activities [4][20][21] - The LEAP I 28 strategy is progressing, with a focus on enhancing operational leverage and functional scalability [4][5][20] - A new organizational structure was implemented to accelerate strategy execution and improve alignment across geographic platforms [4][26][28] Market Trends and Growth Drivers - Strong organic growth was driven by increased energy investments, digital infrastructure development, and demand for corporate risk assessment solutions [4][10][20] - The Americas region saw organic revenue growth of 4.0%, Europe at 4.1%, Asia-Pacific at 8.2%, and the Middle East & Africa at 16.6% [4][40] Shareholder Returns - Bureau Veritas achieved double-digit shareholder returns, supported by a 9% EPS growth at constant currency and a proposed dividend of EUR 0.92 per share, up 2.2% year-on-year [4][13][14] - The new EUR 200 million share buyback program represents approximately 1.5% of outstanding share capital [4][8][13]

Core Insights - The Hangzhou Municipal Government has approved new station names for Metro Line 10 and the Hangzhou-Deqing Intercity Railway, enhancing regional connectivity and industrial development [1] - Yuhang Economic Development Zone is positioned as a key industrial platform in Hangzhou, focusing on smart manufacturing and attracting various industries [3][5] Group 1: Transportation and Infrastructure - Two stations in Yuhang Economic Development Zone have been renamed to reflect their significance in regional transportation: Renhe South Station is now "Dongshanyang Station," and Renhe North Station is "Qihang Road Station" [1] - Qihang Road Station serves as the northern terminus of Metro Line 10's extension and a critical transfer hub for the Hangzhou-Deqing Intercity Railway, enhancing connectivity between Hangzhou and surrounding areas [1] Group 2: Economic Development Zone Overview - Yuhang Economic Development Zone is strategically located in the Yangtze River Delta, providing exceptional geographical advantages and access to major transportation routes [3] - The zone emphasizes smart manufacturing, focusing on new equipment, new materials, and new energy, forming a "One Smart, Three New" industrial system [5] Group 3: Innovation and Research - The zone has partnered with Zhejiang University to establish the Advanced Electrical Equipment Innovation Center, which focuses on research in new energy vehicle systems and intelligent robotics [6] - Over 570,000 square meters of incubation space are available, supporting the growth of enterprises at all stages [6] Group 4: Supportive Policies - Yuhang Economic Development Zone offers substantial support policies for attracting global resources, including equipment subsidies and R&D grants for eligible projects [7] - Specific incentives are provided for integrated circuit and robotics enterprises, promoting industry growth [7] Group 5: Comprehensive Development - The zone is advancing its development philosophy of enhancing the environment, technology, and smart manufacturing to support industrial upgrading [8] - Educational, medical, and residential amenities are being developed to support talent and enterprises, including schools and commercial complexes [8] Group 6: Future Outlook - Yuhang Economic Development Zone aims to enhance its smart manufacturing capabilities and achieve national-level economic and technological development status through continuous improvements in its ecosystem and business environment [9]

Core Viewpoint - Basilea Pharmaceutica Ltd has received a USD 6 million award from BARDA to further develop its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary tract infections (cUTIs) [1][2]. Group 1: Funding and Development - The funding from BARDA will support the preparation of clinical phase 3 studies for ceftibuten-ledaborbactam etzadroxil, which addresses the unmet medical need for oral treatment of cUTIs caused by multidrug-resistant bacteria [2]. - Under the contract with BARDA, Basilea could receive up to USD 147 million in additional non-dilutive funding upon completing predefined milestones [2]. Group 2: Product Information - Ceftibuten-ledaborbactam etzadroxil is a combination of a novel broad-spectrum beta-lactamase inhibitor and an oral cephalosporin antibiotic, which has shown effectiveness against resistant strains of Enterobacterales [4]. - The drug has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for cUTI and uncomplicated urinary tract infections, indicating its potential significance in treating these conditions [4]. Group 3: Market Context - Complicated urinary tract infections, including pyelonephritis, are common bacterial infections with increasing resistance, leading to limited effective oral antibiotic options [5]. - Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations effective against resistant Enterobacterales, highlighting the market need for ceftibuten-ledaborbactam etzadroxil [5]. Group 4: Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, focused on developing innovative drugs for severe bacterial and fungal infections [6][7]. - The company has successfully launched two hospital brands, Cresemba and Zevtera, and has a portfolio of preclinical and clinical anti-infective assets [6][7].